Spotlight on Oncology

Credits: 0.50 CME / MOC
Nonmelanoma Skin Cancers: Real-World Perspectives on Individualizing Care—Case Challenges in NMSC Management
Michael R. Migden, MD
AKH Inc., Advancing Knowledge in Healthcare

Nonmelanoma Skin Cancers: Real-World Perspectives on Individualizing Care—Case Challenges in NMSC Management

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC point(s)
Released: May 13, 2021
Expires: May 12, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Assess safety and efficacy data for checkpoint inhibitors in advanced cutaneous squamous cell carcinoma (CSCC)
  • Outline approaches in shared decision making to improve outcomes and quality of life in patients with advanced CSCC
  • Evaluate current and emerging options for systemic treatment in advanced basal cell carcinoma (BCC)
  • Employ shared decision making, quality of life assessment and management, and collaborative care to improve outcomes in patients with advanced BCC

Activity Description

In this activity, experts in the treatment of advanced nonmelanoma skin cancers (NMSC) will review 2 case challenges—one in CSCC and the other in BCC—that highlight the latest data and offer learners a unique opportunity to rethink key clinical decisions for optimal patient outcomes.

Statement of Educational Need

Clinicians need exposure to the latest advances in the management of advanced NMSC, and insight into optimal integration of key data with patient perspectives in the shared decision-making process.

Faculty

Michael R. Migden, MD
Professor, Department of Dermatology, Division of Internal Medicine
University of Texas MD Anderson Cancer Center
Houston, TX


Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and reviewers have no relevant financial relationships to disclose.

Michael R. Migden, MD, has affiliations with Regeneron, Sanofi, Sun Pharmaceuticals (Consultant).

Ahmad Tarhini, MD, PhD, has affiliations with Bristol Myers Squibb, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Sanofi-Genzyme/Regeneron (Consultant); Clinigen, Genentech-Roche, OncoSec (Contracted Research).

Brian Christensen – Patient, has no financial relationships to disclose.
Tom Hunter – Patient, has no financial relationships to disclose.

RMEI Disclosures
Elizabeth Johnson, MA, RMEI Reviewer, has disclosed no financial relationships.
Laurie Orloski, PharmD, RPh, RMEI Medical Writer, has disclosed no financial relationships.
Sharon Powell, RMEI Senior Medical Editor, has disclosed no financial relationships.
Yael Waknine, RMEI Medical Director, has disclosed no financial relationships.

AKH Disclosures
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer, has disclosed no financial relationships.

AKH Inc. and RMEI planners and reviewers disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre-/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC point(s)
Released: May 13, 2021
Expires: May 12, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Assess safety and efficacy data for checkpoint inhibitors in advanced cutaneous squamous cell carcinoma (CSCC)
  • Outline approaches in shared decision making to improve outcomes and quality of life in patients with advanced CSCC
  • Evaluate current and emerging options for systemic treatment in advanced basal cell carcinoma (BCC)
  • Employ shared decision making, quality of life assessment and management, and collaborative care to improve outcomes in patients with advanced BCC

Activity Description

In this activity, experts in the treatment of advanced nonmelanoma skin cancers (NMSC) will review 2 case challenges—one in CSCC and the other in BCC—that highlight the latest data and offer learners a unique opportunity to rethink key clinical decisions for optimal patient outcomes.

Statement of Educational Need

Clinicians need exposure to the latest advances in the management of advanced NMSC, and insight into optimal integration of key data with patient perspectives in the shared decision-making process.

Faculty

Michael R. Migden, MD
Professor, Department of Dermatology, Division of Internal Medicine
University of Texas MD Anderson Cancer Center
Houston, TX


Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and reviewers have no relevant financial relationships to disclose.

Michael R. Migden, MD, has affiliations with Regeneron, Sanofi, Sun Pharmaceuticals (Consultant).

Ahmad Tarhini, MD, PhD, has affiliations with Bristol Myers Squibb, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Sanofi-Genzyme/Regeneron (Consultant); Clinigen, Genentech-Roche, OncoSec (Contracted Research).

Brian Christensen – Patient, has no financial relationships to disclose.
Tom Hunter – Patient, has no financial relationships to disclose.

RMEI Disclosures
Elizabeth Johnson, MA, RMEI Reviewer, has disclosed no financial relationships.
Laurie Orloski, PharmD, RPh, RMEI Medical Writer, has disclosed no financial relationships.
Sharon Powell, RMEI Senior Medical Editor, has disclosed no financial relationships.
Yael Waknine, RMEI Medical Director, has disclosed no financial relationships.

AKH Disclosures
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer, has disclosed no financial relationships.

AKH Inc. and RMEI planners and reviewers disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre-/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Oncology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
Improving Survival for Veterans with Bladder Cancer – Translating New Knowledge into Clinical Practice

Improving Survival for Veterans with Bladder Cancer – Translating New Knowledge into Clinical Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 16, 2021
Expires: July 15, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with bladder cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Describe the current immune checkpoint inhibitors and guidelines for their use in patients with locally advanced or metastatic UC 
  2. Select appropriate strategies for the early detection and management of immune-related adverse events 
  3. Evaluate the latest clinical data on emerging and recently approved targeted approaches for the treatment of advanced and metastatic UC, including FGFR inhibitors, antibody-drug conjugates, and gene therapy 
  4. Formulate informed treatment plans for patients with locally advanced or metastatic UC within the VHA/MHS/DoD healthcare system based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations 

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of bladder cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Best practices for UC are changing rapidly as new data continually emerges. Within the last 5 years, treatment of advanced and metastatic UC has expanded beyond chemotherapy to include ICIs, molecular targeted agents (ie, FGFR inhibitors), and ADCs. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. The rapidly expanding and evolving treatment landscape is challenging clinicians to stay abreast of latest advances. Lack of awareness regarding frequently updated guidelines, emerging clinical data, and optimal use of recently approved therapies may contribute to suboptimal care of patients with locally advanced and metastatic UC. Therefore, expert guidance in navigating the increasingly complicated treatment paradigm will benefit clinicians’ education, and ultimately improve outcomes for patients within the VHA/MHS/DoD healthcare system.

Faculty

Matthew D. Galsky, MD, FASCO
Professor of Medicine
Acting Chief, Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Translational Research
Tisch Cancer Institute
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Galsky has consulted for:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck, RAPPTA Therapeutics, Dragonfly, Dracen, NuMab, Astellas, Seagen, EMD/Serono, Pfizer

Dr. Galsky has research grants from:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Gilead, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 16, 2021
Expires: July 15, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with bladder cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Describe the current immune checkpoint inhibitors and guidelines for their use in patients with locally advanced or metastatic UC 
  2. Select appropriate strategies for the early detection and management of immune-related adverse events 
  3. Evaluate the latest clinical data on emerging and recently approved targeted approaches for the treatment of advanced and metastatic UC, including FGFR inhibitors, antibody-drug conjugates, and gene therapy 
  4. Formulate informed treatment plans for patients with locally advanced or metastatic UC within the VHA/MHS/DoD healthcare system based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations 

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of bladder cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Best practices for UC are changing rapidly as new data continually emerges. Within the last 5 years, treatment of advanced and metastatic UC has expanded beyond chemotherapy to include ICIs, molecular targeted agents (ie, FGFR inhibitors), and ADCs. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. The rapidly expanding and evolving treatment landscape is challenging clinicians to stay abreast of latest advances. Lack of awareness regarding frequently updated guidelines, emerging clinical data, and optimal use of recently approved therapies may contribute to suboptimal care of patients with locally advanced and metastatic UC. Therefore, expert guidance in navigating the increasingly complicated treatment paradigm will benefit clinicians’ education, and ultimately improve outcomes for patients within the VHA/MHS/DoD healthcare system.

Faculty

Matthew D. Galsky, MD, FASCO
Professor of Medicine
Acting Chief, Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Translational Research
Tisch Cancer Institute
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Galsky has consulted for:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck, RAPPTA Therapeutics, Dragonfly, Dracen, NuMab, Astellas, Seagen, EMD/Serono, Pfizer

Dr. Galsky has research grants from:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Gilead, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME
The France Foundation
Conquer the Clot: Addressing VTE in Your Patients With Cancer

Conquer the Clot: Addressing VTE in Your Patients With Cancer

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 7, 2021
Expires: July 6, 2022
60 minutes to complete

Provided By

Target Audience

This activity is intended for hematologists/oncologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other health care professionals who are involved in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.

Learning Objectives

  • Identify appropriate patients for primary VTE prophylaxis through risk stratification assessments
  • Establish a plan for prevention of VTE in patients at elevated risk
  • Select appropriate therapy to treat VTE in patients with cancer, and select appropriate duration of treatment
  • Discuss with patients the risk and prevention of VTE

Activity Description

This 60-minute session provides education to the oncology team to support guideline-recommended care of patients with cancer, specifically related to: 1) appropriate VTE risk assessment and prophylaxis; 2) individualized VTE treatment; and 3) effective patient communication strategies related to VTE risk, prevention, and treatment. Throughout the session, the content is anchored in patient-care videos to engage the learner.

Statement of Educational Need

The prevention and treatment of cancer-associated thrombosis remains one of the most challenging areas of clinical medicine due to the intersection of cancer care and thrombosis management. Despite recent advances in patient risk stratification, prevention efforts, and treatment strategies, which have provided clinicians and patients with unprecedented management choices, individualized patient-centered management is needed to deliver optimal care.

Agenda

Know the Risk: Are Your Patients Protected? - Michael B. Streiff, MD, FACP
Critical Care: Preventing Cancer Associated Thrombosis in Your Patients - Alok A. Khorana, MD, FACP, FASCO
Conquer the Clot: Treating VTE in Your Patients With Cancer - Tzu-Fei Wang, MD, MPH

Faculty

Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Chair in Oncology Research
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Taussig Cancer Institute and Case Comprehensive Cancer Center
Cleveland, Ohio


Michael B. Streiff, MD, FACP
Professor of Medicine and Pathology
Medical Director, Johns Hopkins Anticoagulation Service
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chairman, NCCN Guidelines for Venous Thromboembolic Disease
Baltimore, Maryland


Tzu-Fei Wang, MD, MPH
Associate Professor, Division of Hematology, Department of Medicine
University of Ottawa at The Ottawa Hospital
Associate Scientist
Ottawa Hospital Research Institute
Ottawa, Canada

Faculty Disclosures

The faculty listed below report that they have relevant financial relationships to disclose:

  • Alok A. Khorana, MD, FACP, FASCO, serves as a consultant for Anthos, Bayer, BMS, Halozyme, Janssen, and Sanofi.
  • Michael B. Streiff, MD, FACP, serves as a consultant for Bayer, Bristol-Myers Squibb, Coagulo, Dispersol, Janssen, and Pfizer. He also receives research support from AHRQ, Janssen, NIH/NHLBI, Novo Nordisk, PCORI, Sanofi, and Tremeau.
  • Tzu-Fei Wang, MD, MPH, serves as a consultant for Servier. She also receives contract research support from Leo Pharma.

Accreditation Statement

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of at least 75% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Statement of Commercial Support

This activity is supported by an educational grant from the BMS/Pfizer Alliance.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 7, 2021
Expires: July 6, 2022
60 minutes to complete

Provided By

Target Audience

This activity is intended for hematologists/oncologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other health care professionals who are involved in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.

Learning Objectives

  • Identify appropriate patients for primary VTE prophylaxis through risk stratification assessments
  • Establish a plan for prevention of VTE in patients at elevated risk
  • Select appropriate therapy to treat VTE in patients with cancer, and select appropriate duration of treatment
  • Discuss with patients the risk and prevention of VTE

Activity Description

This 60-minute session provides education to the oncology team to support guideline-recommended care of patients with cancer, specifically related to: 1) appropriate VTE risk assessment and prophylaxis; 2) individualized VTE treatment; and 3) effective patient communication strategies related to VTE risk, prevention, and treatment. Throughout the session, the content is anchored in patient-care videos to engage the learner.

Statement of Educational Need

The prevention and treatment of cancer-associated thrombosis remains one of the most challenging areas of clinical medicine due to the intersection of cancer care and thrombosis management. Despite recent advances in patient risk stratification, prevention efforts, and treatment strategies, which have provided clinicians and patients with unprecedented management choices, individualized patient-centered management is needed to deliver optimal care.

Agenda

Know the Risk: Are Your Patients Protected? - Michael B. Streiff, MD, FACP
Critical Care: Preventing Cancer Associated Thrombosis in Your Patients - Alok A. Khorana, MD, FACP, FASCO
Conquer the Clot: Treating VTE in Your Patients With Cancer - Tzu-Fei Wang, MD, MPH

Faculty

Alok A. Khorana, MD, FACP, FASCO
Sondra and Stephen Hardis Chair in Oncology Research
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Taussig Cancer Institute and Case Comprehensive Cancer Center
Cleveland, Ohio


Michael B. Streiff, MD, FACP
Professor of Medicine and Pathology
Medical Director, Johns Hopkins Anticoagulation Service
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chairman, NCCN Guidelines for Venous Thromboembolic Disease
Baltimore, Maryland


Tzu-Fei Wang, MD, MPH
Associate Professor, Division of Hematology, Department of Medicine
University of Ottawa at The Ottawa Hospital
Associate Scientist
Ottawa Hospital Research Institute
Ottawa, Canada

Faculty Disclosures

The faculty listed below report that they have relevant financial relationships to disclose:

  • Alok A. Khorana, MD, FACP, FASCO, serves as a consultant for Anthos, Bayer, BMS, Halozyme, Janssen, and Sanofi.
  • Michael B. Streiff, MD, FACP, serves as a consultant for Bayer, Bristol-Myers Squibb, Coagulo, Dispersol, Janssen, and Pfizer. He also receives research support from AHRQ, Janssen, NIH/NHLBI, Novo Nordisk, PCORI, Sanofi, and Tremeau.
  • Tzu-Fei Wang, MD, MPH, serves as a consultant for Servier. She also receives contract research support from Leo Pharma.

Accreditation Statement

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF) and the International Society on Thrombosis and Haemostasis (ISTH). TFF is accredited by the ACCME to provide continuing medical education for physicians.

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. Review the activity objectives and CME/CE information.
  2. Complete the CME/CE activity.
  3. Complete the online posttest. A score of at least 75% is required to complete this activity. The participant may take the test until successfully passed.
  4. Complete the CME/CE evaluation/attestation form. This form provides each participant the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

Statement of Commercial Support

This activity is supported by an educational grant from the BMS/Pfizer Alliance.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF and the ISTH require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and the ISTH do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Description

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced NSCLC.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Description

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced NSCLC.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Understanding Checkpoint Inhibitors in NSCLC

Understanding Checkpoint Inhibitors in NSCLC

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

1.00 CME / CNE / CPE
Rush University Medical Center
Expanding Treatment Options for Advanced Hepatocellular Carcinoma: Understanding the Evolving Role of Systemic Therapies

Expanding Treatment Options for Advanced Hepatocellular Carcinoma: Understanding the Evolving Role of Systemic Therapies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 22, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hepatocellular carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical evidence regarding the safety and efficacy of TKIs and immune checkpoint inhibitors for the treatment of advanced HCC
  2. Identify and manage adverse events associated with the use of TKIs or immune checkpoint inhibitors to optimize patient outcomes
  3. Formulate individualized, evidence-based best-practice treatment plans for patients with advanced HCC, including consideration of prognostic factors, distinct target profiles, and safety considerations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hepatocellular carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In recent years, numerous new targeted and immunotherapy agents have become available for the treatment of HCC, expanding the treatment options for the disease. However, the optimal use of these agents is still being defined based on emerging clinical data. Given the recent advances in available systemic and targeted therapies, an educational program addressing these topics is urgently needed so community clinicians are better equipped to formulate individualized treatment plans for their patients using the most recent best-practice clinical approaches.

Faculty

Ghasson K. Abou-Alfa, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Abou-Alfa has consulted for:
Agios, AstraZeneca, Alnylam, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MINA, QED, Redhill, Rafael, Silenseed, Sillajen, Sobi, Surface Oncology, Therabionics, Twoxar, Vector, Yiviva

Dr. Abou-Alfa has research grants from:
Arcus, Agios, AstraZeneca, Bayer BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Sillajen, Yiviva

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Exelixis and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 22, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hepatocellular carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical evidence regarding the safety and efficacy of TKIs and immune checkpoint inhibitors for the treatment of advanced HCC
  2. Identify and manage adverse events associated with the use of TKIs or immune checkpoint inhibitors to optimize patient outcomes
  3. Formulate individualized, evidence-based best-practice treatment plans for patients with advanced HCC, including consideration of prognostic factors, distinct target profiles, and safety considerations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hepatocellular carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In recent years, numerous new targeted and immunotherapy agents have become available for the treatment of HCC, expanding the treatment options for the disease. However, the optimal use of these agents is still being defined based on emerging clinical data. Given the recent advances in available systemic and targeted therapies, an educational program addressing these topics is urgently needed so community clinicians are better equipped to formulate individualized treatment plans for their patients using the most recent best-practice clinical approaches.

Faculty

Ghasson K. Abou-Alfa, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Abou-Alfa has consulted for:
Agios, AstraZeneca, Alnylam, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MINA, QED, Redhill, Rafael, Silenseed, Sillajen, Sobi, Surface Oncology, Therabionics, Twoxar, Vector, Yiviva

Dr. Abou-Alfa has research grants from:
Arcus, Agios, AstraZeneca, Bayer BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Sillajen, Yiviva

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Exelixis and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.75 CME / MOC / CNE
RMEI Medical Education, LLC
Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Start

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

1.00 CME / CNE / CPE
Rush University Medical Center
Advances in CAR T-Cell Therapies: Optimizing Outcomes and Implementation in Hematologic Malignancies

Advances in CAR T-Cell Therapies: Optimizing Outcomes and Implementation in Hematologic Malignancies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 9, 2021
Expires: June 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest developments in CAR T-cell therapies for relapsed/refractory hematologic malignancies, including ongoing clinical trials.
  2. Identify adverse effects associated with CAR T-cell therapies in hematologic malignancies and describe effective approaches to appropriately manage these effects.
  3. Outline factors that interfere with the application of CAR T-cell therapies and formulate strategies to overcome these barriers.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hematologic malignancies. This educational activity will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in CAR T-cell therapies for hematologic malignancies, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the application of CAR T-cell therapy, ongoing clinical trials of CAR T-cell therapies, appropriate management of associated adverse effects, and best practices to overcome barriers associated with implementation of this treatment approach.

Faculty

Caron Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Conflict of Interest Policy/Disclosure Statement

Dr. Jacobson has consulted for:
Kite/Gilead, Novartis, BMS/Celgene, Nkarta, Lonza, bluebird bio, Precision Biosciences, Abbvie, Ipsen

Dr. Jacobson has research grants from
Pfizer, Kite Pharma

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS, Gilead, Janssen Biotech, Inc., and Kite Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 9, 2021
Expires: June 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest developments in CAR T-cell therapies for relapsed/refractory hematologic malignancies, including ongoing clinical trials.
  2. Identify adverse effects associated with CAR T-cell therapies in hematologic malignancies and describe effective approaches to appropriately manage these effects.
  3. Outline factors that interfere with the application of CAR T-cell therapies and formulate strategies to overcome these barriers.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hematologic malignancies. This educational activity will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in CAR T-cell therapies for hematologic malignancies, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the application of CAR T-cell therapy, ongoing clinical trials of CAR T-cell therapies, appropriate management of associated adverse effects, and best practices to overcome barriers associated with implementation of this treatment approach.

Faculty

Caron Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Conflict of Interest Policy/Disclosure Statement

Dr. Jacobson has consulted for:
Kite/Gilead, Novartis, BMS/Celgene, Nkarta, Lonza, bluebird bio, Precision Biosciences, Abbvie, Ipsen

Dr. Jacobson has research grants from
Pfizer, Kite Pharma

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS, Gilead, Janssen Biotech, Inc., and Kite Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.25 CME / MOC
Postgraduate Institute for Medicine
Basal Cell Carcinoma: To Targeted Therapy and Beyond – High-Risk Basal Cell Carcinoma: Navigating Treatment and Complications

Basal Cell Carcinoma: To Targeted Therapy and Beyond – High-Risk Basal Cell Carcinoma: Navigating Treatment and Complications

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: June 4, 2021
Expires: June 3, 2022
15 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with basal cell carcinoma (BCC).

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess current treatment options for the management of high-risk basal cell carcinoma (BCC)

Activity Description

Treatment decisions in basal cell carcinoma (BCC) are driven by estimated risk for recurrence. Although surgery is the treatment of choice for the majority of high-risk BCC, some large, deep, aggressive, or recurrent tumors can be classified as locally advanced and are best treated with systemic therapy. This Infographic activity provides detailed education on identifying high-risk BCC, the rationale for Mohs surgery, and appropriate use of local therapies. The role and place of systemic therapy is also defined, with an emphasis on the efficacy and limitations of Hedgehog pathway inhibitors (HPI) and the recent emergence of immunotherapy on the treatment landscape.

Statement of Educational Need

Current guideline-based recommendations for treating high-risk BCC, including lesions not amenable to surgery or radiation.

Faculty

Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosures:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objective and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: June 4, 2021
Expires: June 3, 2022
15 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with basal cell carcinoma (BCC).

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess current treatment options for the management of high-risk basal cell carcinoma (BCC)

Activity Description

Treatment decisions in basal cell carcinoma (BCC) are driven by estimated risk for recurrence. Although surgery is the treatment of choice for the majority of high-risk BCC, some large, deep, aggressive, or recurrent tumors can be classified as locally advanced and are best treated with systemic therapy. This Infographic activity provides detailed education on identifying high-risk BCC, the rationale for Mohs surgery, and appropriate use of local therapies. The role and place of systemic therapy is also defined, with an emphasis on the efficacy and limitations of Hedgehog pathway inhibitors (HPI) and the recent emergence of immunotherapy on the treatment landscape.

Statement of Educational Need

Current guideline-based recommendations for treating high-risk BCC, including lesions not amenable to surgery or radiation.

Faculty

Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosures:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objective and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.

1.00 CME / CNE / CPE
Rush University Medical Center
Optimizing Outcomes in Head & Neck Cancer with Immunotherapeutic Strategies

Optimizing Outcomes in Head & Neck Cancer with Immunotherapeutic Strategies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 21, 2021
Expires: May 20, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with head and neck cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Incorporate recently approved immunotherapies into clinical treatment of patients with head and neck cancer
  2. Evaluate recent clinical trial data on immunotherapy-based approaches for treating head and neck cancer
  3. Explain how biomarkers may help with treatment selection, prediction of toxicities, and monitoring treatment response in head and neck cancer patients
  4. Develop strategies to identify and manage adverse events associated with immunotherapies

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of head and neck cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In regard to treating patients with head and neck cancers, education in the areas of emerging immunotherapy-based treatment regimens, biomarkers, and management of immunotherapy-related toxicity is of great relevance to all providers caring for these patients. As new immunotherapy-based treatment strategies enter clinical use, clinicians must be aware of the latest clinical advances and best-treatment practices in order to provide optimal care for patients with head and neck cancer.

This educational activity aims to address this gap in clinician knowledge to improve outcomes for patients with head and neck cancer.

Faculty

Mark Klein, MD
Staff Physician, Minneapolis VA Health Care System
Assistant Professor of Medicine, University of Minnesota
Minneapolis, MN

Conflict of Interest Policy/Disclosure Statement

Dr. Klein has consulted for: n/a

Dr. Klein has research grants from:
Galera Therapeutics - Local Site Investigator for a Clinical Trial for a drug not related to the content of the talk. Dova Pharmaceuticals - Local Site Investigator for a Clinical Trial for a drug not related to the content of the talk. This study is now closed. Cellworks - Research grant to conduct a retrospective cohort study and plan a prospective study in lung cancer. The content of the grant is not related to the current talk. 

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.  

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Merck, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 21, 2021
Expires: May 20, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with head and neck cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Incorporate recently approved immunotherapies into clinical treatment of patients with head and neck cancer
  2. Evaluate recent clinical trial data on immunotherapy-based approaches for treating head and neck cancer
  3. Explain how biomarkers may help with treatment selection, prediction of toxicities, and monitoring treatment response in head and neck cancer patients
  4. Develop strategies to identify and manage adverse events associated with immunotherapies

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of head and neck cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In regard to treating patients with head and neck cancers, education in the areas of emerging immunotherapy-based treatment regimens, biomarkers, and management of immunotherapy-related toxicity is of great relevance to all providers caring for these patients. As new immunotherapy-based treatment strategies enter clinical use, clinicians must be aware of the latest clinical advances and best-treatment practices in order to provide optimal care for patients with head and neck cancer.

This educational activity aims to address this gap in clinician knowledge to improve outcomes for patients with head and neck cancer.

Faculty

Mark Klein, MD
Staff Physician, Minneapolis VA Health Care System
Assistant Professor of Medicine, University of Minnesota
Minneapolis, MN

Conflict of Interest Policy/Disclosure Statement

Dr. Klein has consulted for: n/a

Dr. Klein has research grants from:
Galera Therapeutics - Local Site Investigator for a Clinical Trial for a drug not related to the content of the talk. Dova Pharmaceuticals - Local Site Investigator for a Clinical Trial for a drug not related to the content of the talk. This study is now closed. Cellworks - Research grant to conduct a retrospective cohort study and plan a prospective study in lung cancer. The content of the grant is not related to the current talk. 

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.  

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Merck, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Precision Medicine to Improve Lung Cancer Outcomes: Recent Therapeutic Advances and Emerging Agents

Precision Medicine to Improve Lung Cancer Outcomes: Recent Therapeutic Advances and Emerging Agents

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 14, 2021
Expires: May 13, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with lung cancer.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  1. Describe the common molecular alterations and recommended biomarker testing to inform clinical decision-making for patients with lung cancer.
  2. Assess the latest clinical evidence regarding the safety and efficacy of recently approved therapies for lung cancer.
  3. Formulate informed treatment plans for patients with lung cancer, taking into consideration clinical data regarding combination therapies and sequencing approaches.
  4. Review the mechanism of action and available clinical data for investigational agents under development and their potential role in the context of existing lung cancer treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of lung cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Recent advances in the understanding of molecular alterations associated with treatment outcomes in patients with lung cancer have advanced personalized therapy decisions. However, despite guidelines recommending biomarker testing, a substantial fraction of patients with lung cancer do not receive these tests. Clinicians are challenged to remain abreast of the most recent recommendations regarding biomarker testing, interpretation, and associated treatment options.

Numerous options, including both targeted agents and immunotherapies, have been approved for the treatment of lung cancer in recent years, and data continue to emerge regarding their efficacy, safety, and optimal combinations and sequencing. Given the recent rapid pace of advances, clinicians are challenged to remain aware of the latest clinical outcomes.

In addition to recently approved agents, a wide variety of promising investigational agents targeting common molecular alterations in lung cancer are currently under development. However, clinicians may not be fully aware of the clinical data regarding these emerging therapies or how to place these agents within current lung cancer treatment paradigms.

Faculty

Millie Das, MD
Clinical Associate Professor, Stanford University
Chief, Oncology, VA Palo Alto Health Care System
Palo Alto, CA

Conflict of Interest Policy/Disclosure Statement

Dr. Das has consulted for:
Jazz Pharmaceuticals (ended in July 2020)

Dr. Das has research grants from:
Novartis, Verily, Abbvie, United Therapeutics, Celgene

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 14, 2021
Expires: May 13, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with lung cancer.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  1. Describe the common molecular alterations and recommended biomarker testing to inform clinical decision-making for patients with lung cancer.
  2. Assess the latest clinical evidence regarding the safety and efficacy of recently approved therapies for lung cancer.
  3. Formulate informed treatment plans for patients with lung cancer, taking into consideration clinical data regarding combination therapies and sequencing approaches.
  4. Review the mechanism of action and available clinical data for investigational agents under development and their potential role in the context of existing lung cancer treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of lung cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Recent advances in the understanding of molecular alterations associated with treatment outcomes in patients with lung cancer have advanced personalized therapy decisions. However, despite guidelines recommending biomarker testing, a substantial fraction of patients with lung cancer do not receive these tests. Clinicians are challenged to remain abreast of the most recent recommendations regarding biomarker testing, interpretation, and associated treatment options.

Numerous options, including both targeted agents and immunotherapies, have been approved for the treatment of lung cancer in recent years, and data continue to emerge regarding their efficacy, safety, and optimal combinations and sequencing. Given the recent rapid pace of advances, clinicians are challenged to remain aware of the latest clinical outcomes.

In addition to recently approved agents, a wide variety of promising investigational agents targeting common molecular alterations in lung cancer are currently under development. However, clinicians may not be fully aware of the clinical data regarding these emerging therapies or how to place these agents within current lung cancer treatment paradigms.

Faculty

Millie Das, MD
Clinical Associate Professor, Stanford University
Chief, Oncology, VA Palo Alto Health Care System
Palo Alto, CA

Conflict of Interest Policy/Disclosure Statement

Dr. Das has consulted for:
Jazz Pharmaceuticals (ended in July 2020)

Dr. Das has research grants from:
Novartis, Verily, Abbvie, United Therapeutics, Celgene

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Pages